オハイオにおける白血病の臨床試験
オハイオ内の拠点で、白血病に関する26件の研究が参加者を募集しています。
オハイオ内の都市
公式研究テキスト（英語）
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
0歳〜38歳 · 全性別 · 2026/10/01更新 · NCT06131801Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
- Quetzal Site 8, Columbus
被験者募集中第3相
18歳〜71歳 · 全性別 · 2026/09/23更新 · NCT07504458A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Ohio State University, Columbus
被験者募集中第1/2相
30 Days · 全性別 · 2026/09/16更新 · NCT04065399Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Cleveland
被験者募集中第3相
18歳〜18歳 · 全性別 · 2026/09/08更新 · NCT07509151Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Cinn Children Hosp Medical Center, Cincinnati
被験者募集中第2相
1歳〜18歳 · 全性別 · 2026/09/02更新 · NCT07354074Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT07249346First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/01更新 · NCT07586618Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- UH Seidman Cancer Center, Cleveland
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/20更新 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- Ohio State University, Columbus
被験者募集中第3相
18歳以上 · 全性別 · 2026/08/20更新 · NCT07007312Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第2相
7歳〜25歳 · 全性別 · 2026/08/19更新 · NCT05082519Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
被験者募集中第1/2相
13歳〜90歳 · 全性別 · 2026/08/06更新 · NCT06533579Hairy Cell Leukemia Patient Data Registry
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中観察研究
18歳以上 · 全性別 · 2026/07/02更新 · NCT02560883Integrated Cancer Repository for Cancer Research
- Aultman Alliance Community Hospital, Alliance
- Aultman Hospital, Canton
被験者募集中観察研究健康なボランティア歓迎
19歳〜110歳 · 全性別 · 2026/06/29更新 · NCT02012699A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site, Columbus
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/06/17更新 · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Children's Hospital Medical Center of Akron, Akron
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
全年齢 · 全性別 · 2026/05/18更新 · NCT01790152A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第2/3相
18歳以上 · 全性別 · 2026/04/30更新 · NCT04256317Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
被験者募集中第2相
18歳以上 · 全性別 · 2026/04/15更新 · NCT07356245The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
被験者募集中第1/2相
12歳〜95歳 · 全性別 · 2026/04/15更新 · NCT04329728Shwachman Diamond Syndrome Registry and Study
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中観察研究
全年齢 · 全性別 · 2026/04/06更新 · NCT06056908A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- University Hospitals Cleveland Medical Center, Cleveland
- Cleveland Clinic Taussig Cancer Institute, Cleveland
- The James Cancer Hospital and Solove Research Institute, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2026/03/13更新 · NCT05735184Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- Cincinnati Children's Hospital Medical Center, Cincinnati
被験者募集中第1相
1歳〜39歳 · 全性別 · 2026/02/18更新 · NCT03826992cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
- Cleveland Clinic, Cleveland
被験者募集中観察研究健康なボランティア歓迎
40歳以上 · 全性別 · 2026/01/20更新 · NCT05366881Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Gabrail Cancer Research Center, Canton
被験者募集中第1相
18歳以上 · 全性別 · 2025/10/31更新 · NCT06549790SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Cincinnati
- Massive Bio SYNERGY-AI site, Columbus
- Massive Bio SYNERGY-AI site, Mayfield Heights
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT03452774A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
被験者募集中第1相
18歳以上 · 全性別 · 2025/09/24更新 · NCT06501196Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- University of Cincinnati, Cincinnati
被験者募集中第1相
18歳以上 · 全性別 · 2024/11/15更新 · NCT06034275ClinicalTrials.govより、2026/10/02時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。